Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...

Managing the side effects in patients being treated for metastatic breast cancer can be challenging. Recently, Marla D. Lipsyc-Sharf, MD, a breast medical oncologist and health sciences clinical ...

Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...

EHE treatment is highly individualized, involving surgery, ablation, chemotherapy, and mTOR inhibitors, depending on patient-specific factors. Next-generation sequencing helps identify genetic ...

Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study The mammalian target of rapamycin (mTOR) ...

Groundbreaking studies in mice have sparked a frenzy among longevity enthusiasts—but human trials are still in their infancy. Rapamycin (red) inhibits a protein complex called mTORC1 (mammalian target ...

Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to ...